Hillsdale Investment Management Inc. Purchases Shares of 1,053,800 MiMedx Group, Inc $MDXG

Hillsdale Investment Management Inc. bought a new position in shares of MiMedx Group, Inc (NASDAQ:MDXG) during the fourth quarter, Holdings Channel.com reports. The fund bought 1,053,800 shares of the company’s stock, valued at approximately $7,134,000.

Other institutional investors also recently modified their holdings of the company. First Light Asset Management LLC raised its position in shares of MiMedx Group by 89.5% during the third quarter. First Light Asset Management LLC now owns 3,652,952 shares of the company’s stock worth $25,498,000 after purchasing an additional 1,725,458 shares during the period. Allspring Global Investments Holdings LLC raised its position in shares of MiMedx Group by 433.2% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 289,199 shares of the company’s stock worth $1,958,000 after purchasing an additional 234,958 shares during the period. Vanguard Group Inc. raised its position in shares of MiMedx Group by 5.6% during the fourth quarter. Vanguard Group Inc. now owns 7,184,262 shares of the company’s stock worth $48,637,000 after purchasing an additional 382,623 shares during the period. SG Americas Securities LLC raised its position in shares of MiMedx Group by 16.1% during the fourth quarter. SG Americas Securities LLC now owns 188,045 shares of the company’s stock worth $1,273,000 after purchasing an additional 26,085 shares during the period. Finally, Phocas Financial Corp. raised its position in shares of MiMedx Group by 17.1% during the fourth quarter. Phocas Financial Corp. now owns 492,991 shares of the company’s stock worth $3,338,000 after purchasing an additional 72,037 shares during the period. 79.15% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have recently weighed in on MDXG. Craig Hallum lowered their target price on MiMedx Group from $10.00 to $7.00 and set a “buy” rating on the stock in a research report on Friday, April 17th. Citigroup began coverage on MiMedx Group in a research report on Monday, February 23rd. They set a “market outperform” rating on the stock. Wall Street Zen lowered MiMedx Group from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Weiss Ratings lowered MiMedx Group from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday, May 18th. Finally, Cantor Fitzgerald lowered their target price on MiMedx Group from $12.00 to $8.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 17th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $8.50.

MiMedx Group Trading Up 0.3%

Shares of MiMedx Group stock opened at $3.68 on Friday. The stock has a fifty day simple moving average of $3.70 and a 200 day simple moving average of $5.17. MiMedx Group, Inc has a 12-month low of $3.03 and a 12-month high of $7.99. The company has a market capitalization of $548.14 million, a P/E ratio of 18.40 and a beta of 1.46. The company has a current ratio of 5.39, a quick ratio of 4.81 and a debt-to-equity ratio of 0.07.

MiMedx Group (NASDAQ:MDXG) last announced its quarterly earnings results on Wednesday, April 29th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.02. MiMedx Group had a return on equity of 21.03% and a net margin of 7.88%.The business had revenue of $58.99 million during the quarter, compared to the consensus estimate of $65.80 million. On average, sell-side analysts anticipate that MiMedx Group, Inc will post -0.01 earnings per share for the current fiscal year.

MiMedx Group Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.